Low-dose tenofovir is more potent than adefovir and is effective in controlling HBV viremia in chronic HBeAg-negative hepatitis B

Table 2 Results of treatment with tenofovir disoproxil fumarate (TDF) in the individual patients

Patient(YMDD/WT)	BasalHBVDNA1(cp/mL)	Durationoftreatmentwith TDF(wk)	HBVDNA(end ofTDF)( cp/mL)	Drugsubstituted for TDF	HBV DNAaftersubstitutionof TDF
1 (YMDD)	1000-2000	96	< 1000	ADV	130.000 cp/mL
2 (YMDD)	4.8 × 106	144	< 1000	ADV	No viral
					rebound
3 (YMDD)	1000-2000	56	< 1000	LAM	No viral
					rebound
4 (YMDD)	1000-2000	80	< 10002	ADV + LAM	No viral
					rebound
5 (YMDD)	1000-2000	60	< 1000	ADV	No viral
					rebound
6 WT	< 1000	108	< 1000	ADV	No viral
					rebound
7 WT	< 1000	76	< 1000	ADV	21 000 cp/mL
8 WT	< 1000	88	< 1000	ADV	2700 cp/mL
9 WT	< 1000	116	< 1000	ADV	No viral
					rebound
10 WT	< 1000	52	< 1000	LAM added to	No viral
				TDF	rebound
11 WT	< 1000	24	< 1000	LAM	No viral
					rebound

¹At the end of lamivudine treatment and before starting TDF;

²After 8 mo of TDF, HBVDNA was unchanged but YMDD disappeared. Lamivudine was then added to TDF with prompt decrease of DNA below 1000 cp/mL.